Back to Results

Orexo AB ADR (ORXOY)

Featured in Overvalued Stocks

Orexo AB ADR is a U.S.-traded depositary receipt representing common stock in Orexo AB (publ), a specialty pharmaceutical company based in Uppsala, Sweden. Through its operating business, Orexo develops and commercializes pharmaceuticals and digital therapies in the United States, the European Union, the United Kingdom, and other international markets. Its marketed products include Zubsolv for opioid use disorder, Abstral for breakthrough cancer pain, and Edluar for insomnia. The company also has a development pipeline that includes OX124 and OX125 for opioid overdose-related uses, OX640 for anaphylaxis, and OX-MPI for endometriosis. In digital health, Orexo offers deprexis for depression, vorvida for alcohol management, and modia for opioid use disorder. Orexo also collaborates with Abera Bioscience AB on nasal powder vaccines using its AmorphOX technology.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
OTC-ORXO.Y
$1.66
-6.0% Downside
Fair
—
—
—
Fair
—
—
—
0.0%
October 22, 2026
-1.3x
2.0x
32.6x
59.495 M
28.29 M
1.7%
61.1%
1.7
—
-134.7%
Valuation • Fair Value

Orexo AB ADR (OTC-ORXO.Y) Fair Value by Valuation Model

Compare the primary fair value estimate for Orexo AB ADR (OTC-ORXO.Y) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$1.66

Estimated downside of 6.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$1.04

Earnings power value estimate.

Comps Fair Value

$1.79

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use this section to compare the primary fair value estimate for Orexo AB ADR (OTC-ORXO.Y) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Orexo AB ADR (OTC-ORXO.Y)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

1.712 M

Current operating scale indicator.

Revenue Forecast

137.485 K

Forward revenue estimate.

EBITDA

-32.778 M

Current operating profitability reference.

EBITDA Forecast

-23.053 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Orexo AB ADR (OTC-ORXO.Y) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Orexo AB ADR (OTC-ORXO.Y)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-12.19

No elevated caution signal from this screen.

Altman Z-Score

1.7

Lower score that deserves closer risk review.

FCF / Net Income

-134.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Orexo AB ADR (OTC-ORXO.Y). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Orexo AB ADR (OTC-ORXO.Y)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

October 22, 2026

Days to Earnings

93

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Orexo AB ADR (OTC-ORXO.Y), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Orexo AB ADR (OTC-ORXO.Y) Stock Forecast & Technical Outlook

Review Orexo AB ADR (OTC-ORXO.Y) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Orexo AB ADR (OTC-ORXO.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Orexo AB ADR (OTC-ORXO.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Orexo AB ADR (OTC-ORXO.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Orexo AB ADR (OTC-ORXO.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Orexo AB ADR (OTC-ORXO.Y) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Orexo AB ADR (OTC-ORXO.Y)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Not available

Analyst recommendation data for Orexo AB ADR (OTC-ORXO.Y) is not currently available.

Buy 0
Hold 0
Sell 0
FAQ • Fast Investor Answers

Orexo AB ADR (OTC-ORXO.Y) Stock FAQ

Quick answers about Orexo AB ADR (OTC-ORXO.Y) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$1.66
Estimated downside 6.0%
Valuation Rating
Overvalued
Estimated downside of 6.0%
Analyst Target
Not available
Data is currently unavailable
Financial Health
Fair
Current financial-health read

The current fair value estimate for Orexo AB ADR (OTC-ORXO.Y) is $1.66. This implies an estimated downside of 6.0% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 6.0% versus the current market price.

An analyst price target for Orexo AB ADR (OTC-ORXO.Y) is not currently available in the latest data file.

The current financial health read for Orexo AB ADR (OTC-ORXO.Y) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Orexo AB ADR (OTC-ORXO.Y) is October 22, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Orexo AB ADR (OTC-ORXO.Y) is -1.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Orexo AB ADR is 59.495 M.

The current enterprise value listed for Orexo AB ADR is 28.29 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Orexo AB ADR is OTC-ORXO.Y, and the stock is listed on OTC Markets.

Orexo AB ADR (OTC-ORXO.Y) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Orexo AB ADR is 1.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Orexo AB ADR is 61.1%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on OTC Markets View more

Roche Holding AG Participation (RHHVF) Roche Holding AG Participation (RHHVF)
Roche Holding Ltd ADR (RHHBY) Roche Holding Ltd ADR (RHHBY)
Novartis AG (NVSEF) Novartis AG (NVSEF)
GSK plc (GLAXF) GSK plc (GLAXF)
Chugai Pharmaceutical Co Ltd ADR (CHGCY) Chugai Pharmaceutical Co Ltd ADR (CHGCY)
Merck KGaA ADR (MKKGY) Merck KGaA ADR (MKKGY)
Takeda Pharmaceutical Co., Ltd. (TKPHF) Takeda Pharmaceutical Co., Ltd. (TKPHF)
Bayer AG PK (BAYRY) Bayer AG PK (BAYRY)
UCB SA ADR (UCBJY) UCB SA ADR (UCBJY)
Otsuka Holdings Co Ltd ADR (OTSKY) Otsuka Holdings Co Ltd ADR (OTSKY)
Sandoz Group AG (SDZXF) Sandoz Group AG (SDZXF)
Daiichi Sankyo Co Ltd ADR (DSNKY) Daiichi Sankyo Co Ltd ADR (DSNKY)
Astellas Pharma Inc (ALPMY) Astellas Pharma Inc (ALPMY)
Ipsen SA ADR (IPSEY) Ipsen SA ADR (IPSEY)
Shionogi & Co Ltd ADR (SGIOY) Shionogi & Co Ltd ADR (SGIOY)
CSPC Pharmaceutical Group Ltd (CHJTF) CSPC Pharmaceutical Group Ltd (CHJTF)
Orion Oyj ADR (ORINY) Orion Oyj ADR (ORINY)
Sino Biopharmaceutical Ltd ADR (SBHMY) Sino Biopharmaceutical Ltd ADR (SBHMY)
Eisai Co (ESALF) Eisai Co (ESALF)
Ono Pharmaceutical Co Ltd (OPHLY) Ono Pharmaceutical Co Ltd (OPHLY)
Hikma Pharmaceuticals PLC ADR (HKMPY) Hikma Pharmaceuticals PLC ADR (HKMPY)
Aspen Pharmacare Holdings Ltd ADR (APNHY) Aspen Pharmacare Holdings Ltd ADR (APNHY)
Santen Pharmaceutical Co (SNPHY) Santen Pharmaceutical Co (SNPHY)
Hypera SA ADR (HYPMY) Hypera SA ADR (HYPMY)